The vaccines raised no safety concerns and generated similar levels of antibodies to a natural infection, they said, paving the way for more comprehensive Phase 3 trials to test efficacy.
Strong responses in participants who had recovered from Covid-19 indicate the shot's value as a possible booster, something the companies are exploring independently of the main vaccine. A global Phase 3 study is expected to start in the coming weeks, possibly leading to an approved vaccine in the last quarter of 2021.
Roger Connor, who leads GSK’s vaccines division, said the company believes the vaccine “can make a significant contribution to the ongoing fight against Covid-19” and said the companies are working towards “making it available before the end of the year.”The Phase 3 trial, which the companies said is expected to enroll more than 35,000 adult volunteers, will assess the efficacy of the vaccine against the Wuhan and South African variants of the virus .
People die to live freely in their hometown. If we remain silent, the attacks will continue. If there is injustice somewhere and the world is silent, the world is in danger. HopeToGaza
Can we go somewhere today?
'The risk of something like this happens again from that lab or another Chinese lab is very real,' Pompeo said. “(China is) operating/conducting activities...to secure those facilities. Risk of bioweapons/bioterror emanating from this region is very real.'